1 Followers
23 Following
lifesciencestransformationalhealthcare

Life Sciences & Transformational Health

Unprecedented access to a world of information has given rise to the empowered, albeit distrustful, consumer. So is the case with healthcare, where the patient has been rendered more informed and conscientious thanks to the extraordinary penetration of the Internet. The discerning patient now demands more affordable, sophisticated, transparent, and personalized healthcare services, creating the need for new models for care.

 

Orthopedic Surgical Robots Market Expand At The Fastest CAGR 13% During The Forecast Period 2029

Orthopedic surgical robots have gained immense popularity over the years. Consistent advancements in the technology for orthopedic surgical robots, the availability of orthopedic surgical robots across the globe, and increase in government funding and investments by manufacturers for the development of orthopedic surgical robots are among the primary factors that are anticipated to fuel the demand for orthopedic surgical robots during the forecast period.

 

According to the latest research by PMR, the global orthopedic surgical robots market is expected to account for more than US$ 4,100 million in terms of value by the end of 2029. The orthopedic surgical robots market report also projects a significant growth potential with an anticipated average Y-o-Y growth rate of nearly 13% during the forecast period.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/28777

 

With increasing emphasis on value-based outcomes and reducing costs associated with hospital stays, the benefits offered to patients by procedures carried out using orthopedic surgical robots have the potential to help this cause. Orthopedic surgical robots are associated with advantages such as better visualization of the operating field and lessened tremor.

 

In some of these procedures using orthopedic surgical robots, the advantages also include less blood loss, lower conversion rates, and shorter hospital stays. However, more randomized trials are required to establish the cost-effectiveness of these systems in a hospital setting.

 

Tissue Glue And Bio Adhesive Sealants Market Reflecting A CAGR 8.6% During The Forecast Period 2024

The growing demand for advances and highly effective adhesives continues to influence manufacturers to develop alternative glues and cementing materials. In 2015, the global sales of tissue glue and bio-adhesive sealants have been recorded to exceed US$ 1.1 billion, indicating a promising scope of growth in terms of revenues. According to Persistence Market Research’s recent report titled “Tissue Glue and Bio-adhesive Sealants Market: Global Industry Analysis & Forecast, 2016-2024” global revenues will reach US$ 2,281.2 million by the end of 2024.

By end-user, hospitals will dominate global revenues, as compared to specialty clinics and ambulatory surgical centers (ASCs). In terms of application, the report has forecasted cardiovascular surgeries to account for the highest revenue share. Surpass one billion dollar mark by 2024.

Ethicon Inc. & Baxter International: Dominant Market Players

Local and regional pharmaceutical manufacturers have been actively participating in the global tissue glue and bio-adhesive sealants market, collectively accounting for 14%-15% market share. Key findings from the research have indicated that Ethicon, Inc., a Johnson & Johnson subsidiary that manufactures wound sealing devices and surgical sutures is the largest player in the global market. With over 40% company share, Ethicon (US) has independently expanded its outright dominance in the global tissue glue and bio-adhesive sealants market.

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/12898

Second in line is US-based medical products manufacturer, Baxter International Inc., which contributes to an estimated 22.6% share of global market revenues.

 

Rna Based Therapeutics And Vaccines Market Assessed To Document Most CAGR By Exploitation

Tremendous commercialization has been prominently driving the growth of RNA based therapeutics and vaccines market worldwide. Persistence Market Research projects massive growth prospects for the global RNA based therapeutics and vaccines market over the seven-year period, 2019-2026.

 

Demonstrating herculean expansion at a colossal CAGR, the global market for RNA based therapeutics and vaccines is likely to reach beyond US$ 632 Mn by 2026 end.

 

As indicated by a recently conducted study by PMR, the market for RNA based therapeutics and vaccines will gain a major boost from bolstering research activities, which are witnessing strong governmental as well as private research institutional support over the past few years.

 

While emergence of and growing research interests in RNA based therapeutics and vaccines has broadened the scope of therapeutics targeting a range of health conditions, market study points at a majority of research activities in clinical development.

 

Several governments are offering research funds for RNA based therapeutics and vaccines innovation and research.

Increasing R&D of RNA therapeutics and vaccines that specifically target rare diseases will fuel the growth of market through 2026, as the medical industry currently offers a limited range of treatment alternatives for rare diseases.

 

Company Profiles

  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corp.
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech AG
  • CureVac AG
  • Dicerna Pharmaceuticals, Inc.
  • Regulus Therapeutics, Inc.
  • Marina Biotech, Inc.
  • miRagen Therapeutics
  • Moderna Therapeutics, Inc.
  • Quark Pharmaceuticals, Inc.
  • Santaris Pharma A/S (A Roche Company)
  • Sylentis S.A.
  • Others.
To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/12868

 

PMR expects solid market growth, as industry research experts anticipate RNA based therapeutics and vaccines to soon emerge as potential substitutes of conventional symptomatic therapeutics against unmet disease conditions.

Some of the key players in the global RNA based therapeutics and vaccines market, including Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals, Inc., recently received the FDA orphan drug designation – which is foreseen to the market growth outlook over the next few years.

 

Moreover, strategic collaborations have been one of the top developmental strategies preferred by leading participants in the RNA based therapeutics and vaccines marketplace, besides M&A and technological advancements. Several companies are also identified to be focusing on co-development of RNA therapeutics and vaccines in association with pharma leaders to accelerate research activities.

 

Earlier last year, Arbutus Biopharma Corporation and Gritstone Oncology entered a collaboration and license agreement with an objective to deploy the former’s proprietary lipid nanoparticle (LNP) technology to deliver the latter’s RNA-based neoantigen immunotherapy products.

 

In an effort to gain an expanding market footprint, market participants are concentrating on RNA molecule development against unmet medical conditions. Furthermore, in a bid to slash down the manufacturing costs, companies are also increasingly preferring outsourcing their raw material manufacturing process.

 

Substantial reduction of raw material costs, reduced manufacturing complexities, and advanced analytical methods are presumed to further create an opportunistic space for RNA manufacturers. Value chain expansion and increased operational efficiency are also among the top objectives on which the key players in RNA based therapeutics and vaccines market are likely to work on.

 

For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/12868

 

PMR study indicates that high ROI can be expected due to limited competition in the competitive landscape of the global RNA based therapeutics and vaccines market.

 

While North America continues to represent the most lucrative market for RNA based therapeutics and vaccines, Europe will also remain the next key market globally. According to Persistence Market Research, Asia Pacific and Latin America will exhibit the highest rates of growth over the projection period, attributed to continued prevalence of infectious diseases, pricing flexibility of orphan drugs, and increasing monopolistic power of RNA based therapeutics and vaccines.

 

Dental X Ray Systems Market Envisioned To Create Larger At A Strong

Persistence Market Research (PMR) delivers the key insights on the global dental X-ray systems market in its upcoming report titled “Dental X-ray Systems Market: Global Industry Analysis 2013–2017 and Forecast 2018 – 2026”. In terms of revenue, the global dental X-ray systems market is expected to grow at a promising CAGR of 6.4% during 2018 – 2026.

 

North America is anticipated to contribute a major share in terms of revenue in the global dental X-ray systems market over the forecast period. With an expected value share of around 35%-40% in 2017, the North America dental X-ray systems market is projected to reach US$ 1,111.4 Mn by the end of 2026.

 

The global dental X-ray systems market is segmented based on product type, end users, and regions. Based on product type, the dental X-ray systems market is segmented into Dental X-Ray Systems and Cone-Beam Computed Tomography (CBCT) Systems.

 

The Dental X-Ray Systems segment is expected to hold a significant share of more than 70% in the global dental X-ray systems market owing to growing adoption among end users. In addition, dental X-ray systems are designed to minimize the patient radiation dose. Hand-held intraoral X-ray systems are considered as an alternative to traditional floor-mounted intraoral X-ray systems.

 

In addition, dental X-ray systems are cost-effective equipment when compared with cone-beam computed tomography (CBCT) systems and are expected to contribute to the large share in the global dental X-ray systems market over the forecast period.

 

Whereas, the cone-beam computed tomography (CBCT) systems segment is expected to witness a noteworthy growth in terms of revenue in the global dental X-ray systems market owing to rapid penetration of newly launched devices in the dental X-ray systems market.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/24586

Based on the end user, the global dental X-ray systems market is segmented into dental laboratories, dental hospitals, dental clinics, and others. Among all the end users, the dental clinics are expected to be the leading end user segment in the global dental X-ray systems market over the forecast period.

 

Technological advancements and innovations have brought about major changes in the healthcare industry in the last two decades. This had a tremendous influence in all the branches of dentistry.

 

With the advancements, the necessity for more precise diagnostic tools especially imaging methods have become mandatory. This has provided enormous growth opportunities for the global dental X-ray systems market over the forecast period.

 

The shift from traditional intra-oral X-rays towards advanced imaging techniques such as cone beam computed tomography has also contributed towards the growth of dental X-ray systems market. Increasing numbers of life-threatening diseases such as oral cancer lead to increasing use of dental X-ray systems worldwide.

 

Digital dental X-ray systems is the current key advanced product in the medical devices industry as it has shown promising results with the complications associated with X-ray exposure.

 

Thus, the growing incidence of oral cancer with an increasing number of dental procedures anticipated to drive the growth of the global dental X-ray systems market over the forecast period. Collaborations, partnerships, and mergers among manufacturers for research and development are also expected to boost the growth of the dental X-ray systems market over the forecast period.

 

However, reduced reimbursement and primary healthcare facilities with limited capacity and resources are major factors expected to restrain the growth of the global dental X-ray systems market over the forecast period.

 

For instance, from 2018, the costs for imaging studies performed on computed radiography devices will be reduced by around 7% for the following five years, and 10% after that. The new legislation will impose reimbursement cuts to the technical components for X-rays performed on older technology.

 

The reductions apply to both the Hospital Outpatient Prospective Payment System (HOPPS) and Medicare Physician Fee Schedule (MPFS). This reduced reimbursement for computed radiology equipment is expected to hamper the growth of the global dental X-ray systems market.

 

For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/24586

 

Company Profile

  • Danaher Corporation
  • Dentsply Sirona
  • J. MORITA CORP.
  • FONA
  • Carestream Dental, LLC.
  • Prexion Corporation
  • PLANMECA OY
  • Owandy Radiology
  • Others

High Content Screening Market To Be At Forefront By Approach

The global market for high content screening is currently witnessing the emergence of several notable trends from the product, application, and industry perspective. Growing concerns of pharmaceutical companies towards toxicity studies is shifting focus on secondary cell screening.

 

Further, biotechnology and pharmaceutical companies are deploying high content screening solutions for effective risk assessment of critical illnesses to facilitate efficient drug discovery.

 

Manufacturers in the high content screening market are offering advanced instruments to facilitate various lab services. These factors are currently trending the global market for high content screening, as elucidated in a new research publication by Persistence Market Research.

 

According to the forecast presented in the report, the global high content screening market is projected to register a CAGR of 5.0% during the period 2018 to 2026. Global market revenue is estimated to stand at US$ 1,379.7 Mn by 2018 end, and this is expected to increase to US$ 2,039.9 Mn by 2026.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/12931

 

The last few years have witnessed the development of automated systems for the analysis of cell separation and cellular scalability. An increasing demand for effective therapeutic cell purification protocols is being observed, leading to a surge in adoption of high content screening systems in the coming years. Another factor that is expected to bode well for the high content screening market is the development of advanced software with instrumentation that facilitates both qualitative and statistical image analysis.

 

High content screening systems help pharmaceutical and biotechnology companies extract useful multiplex information from assays, thereby leading to a surge in demand for advanced high content screening systems from the pharmaceutical industry.

 

Advancements in the software and services underpinning high content screening solutions are also being observed in the global market. Being a highly complex software suite, companies in the high content screening market are creating better user-friendly and cloud-based platforms to help address the requirements of end users.

 

Companies are also launching integrated solutions that can meet the varying demands from biological and pharmaceutical companies for advanced cell analysis and cell culture equipment.

 

Companies in the High Content Screening Market Entering Into Strategic Partnerships and Setting Up Manufacturing Hubs at Diverse Locations to Cement Global Market Footing

 

The global market for high content screening is expected to witness several strategic alliances among key players in the near future. One of the main objectives of such collaborations is to be able to offer high content screening instruments to end users on a large scale in the global market.

 

Companies are also looking at the lucrative markets in India and China to expand their geographical presence, owing to the increasing number of biotechnology and pharmaceutical companies and rising investments in healthcare research and development for new drug discovery in these countries.

 

Companies operating in the global high content screening market are also setting up manufacturing facilities across different geographical locations, with a view to cater to the rising local demand and augment their overall market presence across the globe.

 

For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/12931

 

New product launches is another key strategy being adopted by companies in the high content screening market. Being a highly consolidated market, key players offering high content screening solutions are focused on introducing new product lines including consumables, instruments, services, and software; with an objective to sustain their brand name and restrict the entry of new players in the global high content screening market.

 

A heavy pumping in of R&D investments to facilitate new product launches especially catering to the requirements of pharmaceutical companies is another trend being observed in the global market for high content screening. Companies are focusing on developing advanced reagents that are a crucial component of the cellular screening process and are also actively engaged in the marketing and distribution of high content screening solutions in the global market.

 

 

Triple Negative Breast Cancer Treatment Market Research, Studies, Review, Programs And Forecast

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer. Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

 

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the global triple-negative breast cancer treatment market revenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

 

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs. Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare.

 

The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% – 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/14305

 

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

 

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market.

 

Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

 

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

 

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy.

 

Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

 

Company Profiles

  • AstraZeneca PLC
  • Johnson & Johnson Services, Inc.
  • Pfizer, Inc.
  • F. Hoffman – La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Mylan N.V.
  • Eli Lilly and Company
  • Celgene Corporation
  • Sanofi S.A.
  • Others.
For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/14305

 

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

 

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

 

 

Automatic Tube Labelling System Market To Tell Apart Steadfast Growth Within The Course

Over the years, significant advancements and investments in life science research and growth in industrial-level automation have led to improvements in various systems and processes used in life sciences research and development.

 

Labeling of research specimens has moved from tedious, labor-intensive manual forms to a more automated version that enhances productivity, minimizes the chances of errors, reduces costs, and provides more control over lab workflows.

 

Automatic tube labeling systems are more in vogue today, riding on laboratory automation to provide the desired output with increased efficiency to systematically track samples. This is fueling revenue growth of the global automatic tube labeling system market, according to a new research study by Persistence Market Research (PMR).

 

According to forecasts presented in the report, the global market for automatic tube labeling systems is projected to reach a valuation of US$ 75.5 Mn by 2026, up from an estimated US$ 52.6 Mn in 2018. This reflects a CAGR of 4.6% during the eight year period from 2018 to 2026.

 

This growth can be attributed to factors such as enhanced labeling accuracy and reduced downtime facilitated by automatic tube labeling.

 

Automatic tube labeling systems save effort and money and also sample diagnosis time. By minimizing human errors that are characteristic of manual labeling, automatic tube labeling systems help increase productivity and enable drug development companies to achieve a higher output.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/16222

 

Increased Regulatory Compliance to Boost Demand for Automatic Tube Labeling Systems

 

Blood banks, laboratories, and life sciences R&D centers especially in the U.S are mandated to adhere to international standards and guidelines pertaining to the labeling of samples.

 

Pharmaceutical companies for instance, need to follow stringent labeling requirements for product specific labels and barcode standards for specimen shipping and logistics.

 

Incorporation of barcode labeling eliminates the chances of human error in specimen labeling. These stringent regulations pertaining to labeling specimen tubes are acting in favor of the global market for automatic tube labeling, boosting adoption and subsequently revenue growth.

 

Laboratory Automation to Drive Adoption of Automatic Tube Labeling Systems

 

Automation continues to pervade clinical laboratories and research centers that are leveraging technology and digitization to reduce the turnaround time in lab test results, improve results accuracy, and maximize staff productivity – consequently achieving cost savings.

 

Further, lack of a skilled workforce in medical laboratories has placed the onus on automatic solutions as a viable and more efficient alternative to manual labor. Labs are deploying advanced instruments and devices, software and tools, and process methodologies to achieve faster and more accurate test results.

 

This increased dependency and shift towards automation is expected to bode well for the growth of the automatic tube labeling system market.

 

Automation in New Drug Development R&D to Further Fuel Revenue Growth of the Global Automatic Tube Labeling System Market

 

With the increasing incidence of chronic and life-threatening diseases across the world, pharmaceutical companies are pumping in R&D investments in new drug development to address the growing needs of patients. Automation plays a key role in new drug development, as it allows for enhanced speed, accuracy, and efficiency.

 

Experts engaged in new drug R&D activities leverage automation to eliminate cumbersome time and labor intensive tasks such as manual data entry and tubing management. This increased focus on automation in new drug development processes is expected to boost revenue growth of the global automatic tube labeling system market in the near future.

 

For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/16222

 

Developing Economies to Offer Lucrative Growth Opportunities for Manufacturers of Automatic Tube Labeling Systems

 

According to PMR analysis, the emerging markets in the Asia Pacific region are likely to be the new hotbeds of opportunity for key players in the automatic tube labeling system market.

 

A rise in the number of drug R&D centers and laboratories in the developing countries of the APAC such as India and China will drive global demand for automatic tube labeling systems. Several manufacturers of automatic tube labeling systems based in North America and Europe are planning targeted expansion across the Asia Pacific through strategic M&A activities with prominent regional players.

 

Company Profile

  • Computype Inc.
  • PaR Systems, Inc.
  • AutoLabe
  • Scinomix Inc.
  • ALTECH Srl
  • Brooks Automation, Inc.
  • BioMicroLab Inc.
  • California Advanced Labeling, Inc.
  • HTI bio-X GmbH
  • Capmatic Ltd.
  • Others.

Facial Rejuvenation Market To Tell Apart Steadfast Growth Within The Course

According to the latest market report published by Persistence Market Research, titled ‘Global Market Study on Facial Rejuvenation: Early onset of Ageing and Rising Adoption of minimally Invasive Procedures to Drive the Market, the global facial rejuvenation market is expected to expand at a CAGR of 4.9% during the forecast period 2015-2021.

 

The market is segmented based on product type, end-user type, and region. On the basis of product type, the overall market has been segmented into topical products (sunscreens, moisturizers, keratolytic, retinoids, and hair removal creams), botulinum, dermal fillers, chemical peels, microabrasion equipment, and equipment-based treatments such as laser resurfacing and ultrasounds. On the basis of end-user, the market has been segmented into hospitals and dermatology clinics, which include private offices held by leading dermatologists.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/3639

 

By product type, the botulinum products are expected to remain the largest segment, registering highest CAGR of 7% in terms of value, over the forecast period. The longer effectiveness of the treatment and easier availability is expected to contribute to its growing popularity.

 

The botulinum product type segment is expected to reach a market value of US$ 9,796.9 Mn by the end of the forecast period. The product is also expected to emerge as the most preferred treatment type for both patients and physicians, globally, over the forecast period. The second most popular treatment choice is dermal fillers containing hyaluronic acid.

 

On the basis of the end user segment type, the market has been segmented into hospitals and dermatology clinics. Currently, clinics are more preferred to hospitals by patients globally.

 

On the basis of region, the market has been segmented into North America, Latin America, Europe, Asia-Pacific, and the MEA.

 

Early onset of ageing and rising adoption of lesser painful minimally invasive or non-surgical rejuvenation procedures are major factors driving the growth of the global facial rejuvenation market currently.

 

Other trends driving the market growth include easier access to treatments, rising affordability, increasing awareness about more innovative and less painful procedures, deeper penetration of beauty products in the local markets, and demand for quicker results and shorter treatment duration by patients.

 

However, the market is expected to witness regulatory overhaul with an increase in procedure and product standardization during the forecast period (2015–2021).

The absence of standardized regulations is leading to an influx of many local players in both the developed and emerging regions. Furthermore, lack of documented and approved product efficacy is also hampering the growth of this market.

Major players dominate the market in developed regions currently. Local players offer similar local products at 20% – 30% price discounts compared to that offered by renowned and established companies in North America and Europe. This leads to unhealthy competition and could also hamper patient safety.

 

This report assesses trends driving each market segment and offers analysis and insights about the potential of facial rejuvenation therapies in specific regions. North America is estimated to dominate the facial rejuvenation market with the maximum value share of the overall market by the end of 2015. By 2021, North America and Europe markets are expected to account for over three-fifth share of the global facial rejuvenation market revenue. In terms of value, North America is estimated to be the dominant market, registering a CAGR of 7.4% over the forecast period.

 

For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/3639

 

Company Profiles

  • Merz Pharma
  • Anika Therapeutics, Inc.
  • Lumenis
  • Galderma (Nestlé Skin Health)
  • Contura
  • Daewoong Pharmaceutical Co., Ltd.
  • llergan plc (Actavis plc)
  • Others.

Anticancer Drugs Market To Garner Brimfull Sales With The Help

In a recently published market research study, Persistence Market Research presents a detailed opportunity analysis of the global anticancer drugs market, revealing key factors likely to have a significant impact on revenue growth of the anticancer drugs market in the next few years. Over the years, there has been an increasing emphasis on R&D in drug development and therapies for the treatment of different types of cancer.

 

Pharmaceutical companies are introducing novel drug formulations in the global market, thereby expanding the product pipeline for cancer treatment. This is likely to create newer vistas of growth in the anticancer drugs market.

This report published by Persistence Market Research throws light on the revenue projections of the global market for anticancer drugs, which is estimated to reach a whopping valuation of US$ 227 Bn by the end of 2026, up from just under US$ 129 Bn in 2018. This is indicative of a growth rate of 7.4% during the period from 2018 to 2026.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/24355

 

Companies operating in the global anticancer drugs market are also seeking the necessary regulatory approvals for multiple indications to ensure a maximum return on their investment from a single molecular entity.

Immuno-oncology is currently the most active area in cancer research and doctors and research scientists across the world are collaborating to develop newer ways to use immuno-oncology to treat various types of cancers. Immunotherapy is fast gaining traction in the global healthcare sector, with several successful clinical trials that have led to the recent approvals of newer anticancer drugs in the global market.

 

Immunotherapy is finding increasing acceptance among the global medical fraternity over conventional chemotherapy, which until now, had been the first line of treatment for cancer. Immunotherapy is considered a safer alternative to chemotherapy, and companies in the anticancer drugs market are introducing newer portfolios of early checkpoint-based immunotherapy drugs to meet the growing demands from hospitals and healthcare institutions.

With key players queuing up to obtain the necessary regulatory approvals, immunotherapy is slated to grab maximum value share of the global market for anticancer drugs in the near future.

 

Newer Cancer Treatment Options and an Ever-increasing Drugs Pipeline Owing to the Current Spate of Ongoing Clinical Trials to Bode Well for the Anticancer Drugs Market

 

In the last five years, 70 new cancer treatment options have been introduced in the global market and are used by healthcare facilities to treat more than 20 different types of tumors. Innovation is fueling the pipeline of oncology drugs in clinical development and this is only expected to increase in the near future.

 

The pipeline of anticancer drugs in different stages of clinical development has expanded significantly in the last decade, with clinical trials for immunotherapies being the fastest growing within oncology R&D and likely to lead the drugs pipeline by 2020. This indicates the rising demand for anticancer drugs in the global healthcare sector, pushing companies to speed up drugs development and clinical trials and also seek the necessary regulatory approvals. This factor is expected to augment revenues in the global anticancer drugs market.

 

For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/24355

 

Manufacturers of Anticancer Drugs to Expand Their Product Portfolio Through Strategic Partnerships

 

One of the key trends being observed in the anticancer drugs market is the increasing number of partnerships between large biopharmaceutical companies and relatively smaller pharmaceutical companies to retain competitive edge and to beef up their product pipeline. Through partnerships and licensing deals, big pharmaceutical companies are acquiring new product lines from smaller companies while also continuing to enhance their in-house drug development strategies.

Postoperative Pain Management Market Envisioned To Create Larger At A Strong

The number of patients undergoing surgical procedures has increased significantly in the last few years. A notable rise in people suffering from chronic diseases such as cancer is also being witnessed of late.

 

Patients who have undergone surgery require the administration of postoperative pain management drugs within 24 hours of the surgical procedure to reduce moderate to severe postoperative pain. This has led to a spur in demand for postoperative pain management drugs in the global market.

 

Further, there is a steadily growing awareness regarding palliative care among patients suffering from terminal illness. This is boosting the adoption of analgesics as effective postoperative pain management drugs.

 

A new report by Persistence Market Research traces the growth trajectory of the global postoperative pain management market for a period of eight years from 2018 to 2026. According to the revenue projections indicated in the report, the global market for postoperative pain management is likely to cross a whopping US$ 45 Bn in revenue by the end of 2026, up from an estimated valuation of around US$ 30 Bn in 2018.

 

This is reflective of a growth rate of 5.1% during the period 2018 – 2026. The report highlights the various market revenue push and pull factors as well as the trends impacting growth and performance of the global market for postoperative pain management during the aforesaid period of study.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/24259

 

Manufacturers of Postoperative Pain Management Drugs Focused on Developing Formulations with 

Abuse-deterrent Properties

 

The opioid epidemic in the U.S has put extensive regulatory pressure on manufacturers of postoperative pain management drugs to develop opioids with abuse-deterrent properties. Several notable pharmaceutical companies are incorporating abuse-deterrent technologies to manufacture pain management drugs with novel formulations that are safe for consumption by patients without harmful side effects.

 

One of the innovations in the manufacturing of analgesics is the introduction of non-opioid drugs with extended-release of the medication to provide relief to patients from postoperative pain for a longer period of time. This is expected to result in significant revenue growth of the global postoperative pain management market in the coming years.

 

Key Trends Witnessed in the Postoperative Pain Management Market

 

Manufacturers of postoperative pain management drugs are entering into strategic collaborations and partnerships with pharmaceutical companies for developing non-opioid analgesics.

 

The main objectives of these collaborations are – to create an integrated approach towards pain management; to prevent the diversion of prescription opioid medications; and to prevent signs of opioid abuse and addiction. Growing adoption of opioid maintenance treatment (OMT) to treat opioid dependence (OD) is also being observed in the global market.

 

However, the use of OMT is debatable, as some studies claim OMT is also a form of addiction; yet, the use of OMT to treat OD is finding acceptance among the global healthcare fraternity.

 

Manufacturers of non-abuse opioids and analgesics are innovating their drug formulations and packaging formats to ensure that patients do not consume opioids in powder form.

 

In the recent past, the U.S FDA has approved certain new forms of non-abuse opioid drugs and manufacturers are leveraging this commercialization of non-abuse opioids, which reduce the risk of drug misuse, thereby finding widespread adoption among patients as effective pain management drugs.

 

For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/24259

 

There has been a steady focus on palliative care in the case of terminally sick patients, especially in third world countries. Opioids are used in palliative care and the easy availability of reimbursement for these drugs is pushing the consumption of opioids at a global level.

 

The governments of certain developing countries are driving strategic initiatives for the provision of palliative care for patients seeking relief from pain post cancer surgery. This is anticipated to spur the demand for opioids as an effective medication for postoperative pain management.

Uterine Cancer Diagnostic Testing Market Set To Witness An Dealing At Some Purpose

In a recent study on the global uterine cancer diagnostic testing market, leading research firm Persistence Market Research has tracked the growth path of the global market for uterine cancer diagnostic testing over an eight year period from 2018 to 2026.

 

The report features global market numbers and insights on the various factors driving the adoption of advanced uterine cancer diagnostic tests. According to the report, two of the main aspects responsible for a surge in revenue in the global uterine cancer diagnostic testing market are – a rising awareness among the female population pertaining to the various diseases of the uterus, and the availability of different types of direct and combination tests to detect uterine cancer.

 

Persistence Market Research forecasts revenue in the global uterine cancer diagnostic testing market to reach around US$ 3.8 Bn by 2026 end, up from an estimated value of about US$ 2 Bn in 2018. The market is expected to witness a growth rate of 7.8% during the eight year period from 2018 to 2026.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/17005

 

Numerous Tumor Marker Tests Currently Used to Detect Uterine Cancer to Provide a Wide Window of 

 

Opportunity in the Global Market

 

Persistence Market Research analysis indicates that the glycoproteins CA19.9, YKL-40, CA72.4, and CA15.3 are useful markers that help in the diagnosis of patients suffering from endometrial cancer and may provide a wide opportunity as advanced and improved tumor marker tests for uterine cancer diagnostic testing in the coming years. Early detection of endometrial cancer in women with irregular and post-menopausal bleeding (one of the early symptoms of endometrial carcinoma) is also likely to elevate the market for uterine cancer diagnostic testing. BRCA1 and BRCA2 breast cancer mutations are related to the spread of endometrial cancer in women.

 

Ongoing research studies that have linked uterine cancer and BRCA mutation indicate favorable outcomes for early-stage diagnosis and prevention of endometrial cancer, by suggesting a uterine diagnosis post the diagnosis of BRCA1 mutation. This is also anticipated to be a good opportunity area in the uterine cancer diagnostic testing market in the near future.

 

Genetics and Epigenetics Trending the Global Uterine Cancer Diagnostic Testing Market

 

Gene mutations are fast emerging as candidates in the carcinogenesis of endometrial carcinoma and uterine sarcoma. Gene mutations — including K-ras mutations, PTEN, and β-catenin — are being studied for the diagnosis of uterine cancer. Epigenetic factors such as DNA methylation and histone modification are also being studied to improve the rate of uterine cancer diagnosis.

 

Advanced genetics and epigenetics are the latest trends being observed in the uterine cancer diagnostic testing market. Another trend is the age standardization of the women population that can help differentiate women from a specific age group who are more prone to developing tumors that may lead to uterine cancer.

 

A Favorable Reimbursement Scenario to Augur Well for the Global Uterine Cancer Diagnostic Testing Market

 

Improved reimbursement for uterine cancer diagnostic testing services with co-payment models based on the levels of income of people is a positive development in the global market for uterine cancer diagnostic testing. For instance, Medicare offers good reimbursements for uterine cancer diagnostic testing in the U.S.

 

The governments across countries in North America have implemented co-payment reimbursement models that can be adjusted as per the income levels of the population. This is benefiting the global uterine cancer diagnostic testing market.

 

Company Profiles 

  • Abbott
  • Roche Holdings AG
  • Siemens AG
  • Danaher
  • BioMerieux SA
  • Others
For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17005

 

Key Research Findings on the Uterine Cancer Diagnostic Testing Market

 

Persistence Market Research throws light on the top regional growth markets for uterine cancer diagnostic testing; the most prevalent type of uterine cancer; the widely accepted test type to diagnose uterine cancer; and top end users in the uterine cancer diagnostic testing market in this comprehensive research study.

  • North America to remain leading regional market for uterine cancer diagnostic testing, holding over 40% market share by 2026
  • Endometrial carcinoma expected to be the most prevalent cancer type
  • Abdominal ultrasound, hysteroscopy, and CA-125 tumor marker blood test to remain most preferred test type
  • Diagnostic laboratories anticipated to be the top end users
 

Immune Checkpoint Inhibitors Market Development Projected To Achieve An Dealing At Some Purpose

As projected by a new report published by Persistence Market Research (PMR), the global immune checkpoint inhibitors market will exhibit a spectacular expansion over the forecast period, 2017 to 2026. Global sales of immune checkpoint inhibitor drugs are estimated to surpass US$ 30,000 Mn in revenues by 2026-end.

 

Immune Checkpoint Inhibitors are Attracting Interests of Scientists and Drug Developers

 

Cancer has become one of the major causes of deaths worldwide. Oncology research is considered to be a vast field, with several disease indications including few orphan/rare forms. Significant unmet requirements exist for cancer therapeutics, albeit oncology’s significant contribution based on drug development.

 

Drug developers across the globe are now shifting their focus toward immunotherapeutics, wherein a human body’s immune system is leveraged to fight cancer. Various classes of immunotherapeutics such as immune checkpoint inhibitors are now attracting interests of scientists and drug developers. A number of academic institutes and industry contributors are making investments in research and development activities concerning immune checkpoint inhibitors.

 

With an opportunistic pipeline of development, the market is characterized by participation of various well-established as well as niche market players over a common platform. In a bid to gain a firm foothold in the market, various stakeholders are entering into collaborations for increasing their portfolio and global presence.

 

For example, Dynavax Technologies Corporation and Merck are together investigating potential synergistic effects of drug developed by the combination of Dynavax’s SD-101 with Merck’s two immunotherapies viz. MK-1966 and Keytruda. Various niche players in the market are also exploring immune checkpoint inhibitors’ potential in treating patients with cancer through the development of next-generation immune checkpoint inhibitors therapy.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/20122

 

North America and Europe to Lead Global Immune Checkpoint Inhibitors Market in Terms of Revenues

 

In terms of revenues, North America and Europe will continue to lead the global immune checkpoint inhibitors market, however the latter will register a relatively faster expansion through 2026. In addition, Asia-Pacific excluding Japan (APEJ) is projected to ride on the highest CAGR in the market through 2026, followed by Japan.

Growth of the market in APEJ can be highly attributed to rising number of research collaborations between international players and companies in this region. However, the market in Japan will account for comparatively larger revenues than that in APEJ by 2026-end.

 

Although PD-1 among drug class will continue to be the most lucrative, sales of PD-L1 are projected to register the highest CAGR in the global immune checkpoint inhibitors market through 2026. PD-L1 have been deemed successful in treating Merkel cell carcinoma, non-small cell lung cancer, and bladder cancer. In addition, a number of studies are being carried out for use of PD-L1 inhibitors for various other types of cancer. CTLA-4 are anticipated to remain the least lucrative drug class of immune checkpoint inhibitors throughout the forecast period.

 

Key Research Findings from PMR’s Report on Immune Checkpoint Inhibitors

  • Urothelial carcinoma and squamous cell carcinoma are projected to be the fastest growing therapeutic applications of immune checkpoint inhibitors and are collectively poised to account for over 40% revenue share of the market by 2026-end. Sales of immune checkpoint inhibitors for treating colorectal cancer and blood cancers are also expected to witness a robust expansion through 2026.
  • In terms of revenues, hospital pharmacies will continue to be the largest distribution channels for immune checkpoint inhibitors, owing to increasing number of hospital admissions associated with cancer.
For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/20122

 

Company Profile

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Co.
  • Roche Holding AG
  • Incyte Corporation
  • Merck & Co., Inc.
  • Merck KGaA
  • Sanofi
  • Novartis AG
  • Others.
 

Progressive Multifocal Leukoencephalopathy Treatment Market Set To Document Exponential Growth By Means

Progressive multifocal leukoencephalopathy (PML) is a rare, fatal disease that causes continual damage to the white matter of the brain, at different locations. Caused by JC Virus, PML is mostly reported in cancer patients on chronic immunosuppressive medications or those suffering from AIDS. Also, patients with transplants, multiple sclerosis or other variants of autoimmune diseases are susceptible to progressive multifocal leukoencephalopathy.

With no specific treatment, anti-HIV drugs are being increasingly used for controlling progressive multifocal leukoencephalopathy.

 

Considering the rarity of the disease, with no specific treatment options available, the global progressive multifocal leukoencephalopathy treatment market is expected to remain in the low growth-low volume quadrant over the forecast period of 2018-2026, representing a sluggish 2.8% CAGR, predicts Persistence Market Research. The global progressive multifocal leukoencephalopathy treatment market is likely to reach a valuation of US$ 150.5 Mn by 2026 by the end of 2026.

 

While the North America progressive multifocal leukoencephalopathy treatment market is anticipated to be the most lucrative, PML market in Asia Pacific is expected to record comparatively faster growth considering increasing prevalence of HIV infection and awareness.

 

Anti-retroviral therapy, Anti JCV, and other symptomatic drugs for progressive multifocal leukoencephalopathy treatment are available in the market. Symptomatic treatment of progressive multifocal leukoencephalopathy is projected to hold +32% market share in 2018, with significant revenue contribution to the global progressive multifocal leukoencephalopathy treatment market. The trend is closely followed by Anti-retroviral therapy, given to the newly diagnosed patients with HIV infection and PML.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/15679

 

Swelling HIV & Hematological Malignancy Prevalence to Boost Progressive Multifocal 

 

Leukoencephalopathy Treatment Market

 

Increasing prevalence of HIV infection and cancer is expected to boost the growth of global progressive multifocal leukoencephalopathy treatment market. In terms of indication, HIV/AIDS and hematological malignancies collectively accounted for a total value share of +87% of the global progressive multifocal leukoencephalopathy treatment market in 2017.

 

Despite advancements in scientific understanding of HIV and its prevention and treatment coupled with significant efforts by government and civil society organizations, most patients living with HIV or at risk of contracting infection, do not have access to optimal prevention, care, and treatment, more so in middle and low income economies. Delayed treatment exposes patients to more fatal diseases like progressive multifocal leukoencephalopathy.

Studies show that approximately 80% of progressive multifocal leukoencephalopathy patients have AIDS. Use of antiretroviral therapy for HIV-infected patients is expected to boost the global progressive multifocal leukoencephalopathy treatment market.

 

Moreover, growing prevalence of hematological malignancy and early diagnosis of PML as a first line of treatment are key factors promoting the global progressive multifocal leukoencephalopathy treatment market. PML is mostly reported in patients suffering from homological malignancy, solid tumors, and in organ transplant recipients.

Since, overall healthcare investments have significantly increased, across the globe, governments are making efforts to deliver quality treatment and care to HIV patients, typically antiretroviral therapy.

 

Favorable reimbursements and insurance options for HIV and cancer treatment and people with pre-existing HIV conditions, will not just provide financial assistance in low and middle income economies, but also help in early diagnosis of PML, further driving the global progressive multifocal leukoencephalopathy treatment market. Cost-effective diagnosis and treatment camps by Centers for Disease Control and Prevention (CDCP) would further contribute to the global growth of progressive multifocal leukoencephalopathy treatment market.

“Lack of specific treatments and therapies for progressive multifocal leukoencephalopathy treatment is likely to restrict the market growth, considering poor outcomes of the treatment.

 

The current progressive multifocal leukoencephalopathy treatment options focus on immune reconstitution, restoration of immune responses to JC virus infection, and eventual suppression of immune reconstitution inflammatory syndrome”- Principal Healthcare AnalystPersistence Market Research

 

For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15679

 

Company Profile

  • Pfizer, Inc.
  • F. Hoffman – La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Allergan plc (Actavis plc)
  • Overview
  • Novartis AG
  • Mylan N.V.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Others.

Antiseptic Bathing Market Relentless Boom To Be Witnessed

Increase in awareness about hospital acquired infections and growing incidences of surgical site infections supports the growth of antiseptic bathing market. According to a latest research by the company, the global antiseptic bathing market is anticipated to account for over US$ 549.3 Mn in terms of value, by 2026 end.

 

Antiseptic Bathing Market: Overview

 

Globally there are a number of organizations and regulatory bodies that recommend the use of antiseptic bathing products for pre-operative skin cleansing. Regulatory authorities such as the Care Bundles in the U.K. and the Royal College of Surgeons of Ireland that recommend the use of soap for preoperative skin cleansing. Recommendations by other organizations such as the United States of America (USA) Institute for Healthcare Improvement include preoperative antiseptic bathing using CHG soap specifically.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/25045

 

Although, in the APAC regulatory region, the recommendation for using antiseptic bathing products by bodies is not that stringent, some organizations such as the Ministry of Health, Malaysia, recommends the use of 2% CHG for preoperative cleansing.

 

Furthermore, over 75% of healthcare professionals prefer and recommend the adoption of CHG Solutions for preoperative antiseptic bathing. This is one of the main driving force for the growth of the CHG solutions in the global antiseptic bathing market.

 

Antiseptic Bathing Market: Insights

 

CHG wipes are another fast growing segment of the antiseptic bathing market. These are products that have Chlorhexidine Gluconate (CHG) impregnated into wash cloths, wipes, towels and sponges. These products do not need to be dipped in water, however, they need to be warmed in an industrial warmer for patient comfort.

 

Although the CHG wipes are more expensive and increases the cost per bath, these are well adopted in the developed regions for antiseptic bathing since they are easy to use especially for patients who are bed ridden for a long time. Other types of antiseptic bathing products include, antiseptic wipes such as include alcohol wipes and BZK wipes, antiseptic solutions such as BZK solution and antiseptic shampoo caps.

 

Antiseptic Bathing Market: Regional Analysis

 

Asia Pacific is one of the most lucrative regions for the growth of the antiseptic bathing market. This is mainly driven by the increase in geriatric population and increase in the disposable income in Japan is expected to aid the increased demand for more advanced Antiseptic Bathing solutions. Favorable changes in regulatory recommendation towards antiseptic bathing in the region is expected to boost the antiseptic bathing market growth.

 

Other factors that support the growth of the antiseptic bathing market in the APAC region is the prolonged length of stay in hospitals and increasing number of hospital beds over the years. Japan is expected hold a largest value share in the antiseptic bathing market.

 

However, China is expected to be the most lucrative region for antiseptic bathing market since it has a large number of hospitals that have more than 500 beds each which follows bathing protocol to prevent hospital acquired infections.

 

The company has segmented the global antiseptic bathing market based on product type as CHG Bath Towels/Wipes, CHG Solution, Antiseptic Wipes, Antiseptic Bathing Solution, and Antiseptic Shampoo Caps. In terms of revenue, the CHG solution in Antiseptic Bathing will hold significant share over the forecast period. In contrary, the antiseptic shampoo caps segment in Antiseptic Bathing market will exhibit limited investment opportunities, in terms of revenue, through 2026.

 

For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25045

 

Antiseptic Bathing Market: Top Companies

 

Company Profiles

  • Ecolab Inc.
  • 3M Co
  • Reynard Health Supplies
  • Becton, Dickinson & Company
  • Clorox Company
  • Air Liquide (Schulke Australia Pyt Ltd)
  • Molnlycke Health Care AB
  • Medline Industries
  • Stryker Corporation
  • HiCare Health
  • Others.

Confocal Microscope Market To Witness Growth Acceleration At Some Purpose

According to the latest market report published by Persistence Market Research titled ‘Global Confocal Microscope MarketGlobal Industry Analysis 2013 – 2017 and Forecast, 2018 – 2028,’ the global confocal microscope market is projected to reach US$ 1,310.5 Mn by the end of 2028 and grow at a CAGR of 3.3% during the forecast period.

Global Confocal Microscope Market: Dynamics

 

Confocal microscope is a special form of standard fluorescence microscope. Confocal microscopy is different from the conventional wide field fluorescence microscopy, in which the optical path is designed to place in front of the image detector (photomultiplier tube or camera), and an aperture (opening) at a point where the image is focused in conjunction with the focal plane of the image.

 

Government policies and funding for biological research activities and shift towards value-based care are the major factors expected to drive the growth of the market for confocal microscope over the forecast period.

Furthermore, increasing number of research and development activities and technological advancement in microscopy are the other factors expected to spur the growth of the market for confocal microscope over the forecast period.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/16174

 

Increasing spending on research & development and emergence of academia as the primary organization for carrying out basic research will further increase the adoption rate of confocal microscope.

 

Likewise, use of confocal microscope for live cell imaging and confocal microscopy in ophthalmology is also expected to drive the growth of the market for confocal microscope.

 

However, high cost of technologically advanced microscopes and shortage of skilled professionals and expertise are expected to hamper the growth of the Confocal Microscope market.

 

Global Confocal Microscope Market: Forecast

 

The global confocal microscope market is segmented on the basis of product type, and end user. On the basis of product type, the global confocal microscope market is segmented into microscope system, accessories and software. Microscope system is sub segmented into laser scanning confocal microscope, spinning disk confocal microscope and re scan microscope. The microscope systems is expected to be the leading segment in the global confocal microscope market over the forecast period.

 

The microscope systems accounts a total value share of 92.0 % of the global confocal microscope market in 2017. The laser scanning confocal microscope segment is estimated to have incremental opportunity of US$ 200.1 Mn between 2016 and 2028.

 

Among end user, academic & research institute segment is expected to hold high share in the global confocal microscope market owing to increasing number of research in life science applications and rising adoption of confocal microscope in academic research.

 

Geographically, the global confocal microscope market has been segmented into North America, Latin America, Europe, Asia Pacific, Japan and Middle East & Africa.

 

This report assesses the trends driving the growth of each segment and offers analysis and insights into the potential of the confocal microscope market in specific regions. North America accounted a large share in the global market in 2017, and is expected to be the dominant regional market for confocal microscope over the forecast period, owing to increasing spending in research and development.

 

Besides, presence of several key players with a robust distribution network for microscope and collaboration for the development of new techniques are some of the other key factors expected to drive the growth of the confocal microscope market in North America. Asia Pacific is expected to witness rapid growth over the forecast period.

 

For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/16174

 

Global Confocal Microscope Market: Competitive Landscape

  • Olympus Corporation 
  • Leica Microsystem (Sub. Danaher)
  • ZEISS Group (Carl Zeiss Meditec AG)
  • Nikon Corporation
  • Bruker Corporation
  • Bio-Rad Laboratories, Inc
  • Oxford Instruments plc
  • Thorlabs, Inc.
  • Confocal.nl
  • ISS.Inc
  • Others

Immune Repertoire Sequencing Market Expanding Incidence Of Minimally Invasive Ways To Beautify Enlargement

Persistence Market Research (PMR) delivers the key insights on the immune repertoire sequencing market in its upcoming report titled “Immune Repertoire Sequencing Market – Global Industry Analysis 2013 – 2017 and Forecast 2018 – 2026”. In terms of revenue, the immune repertoire sequencing market is projected to register a CAGR of 7.3% over the forecast period, owing to various factors, regarding which PMR offers detailed insights and forecasts in this report.

 

The immune repertoire sequencing market is segmented based on product type, application, end users and regions. Based on product type, the immune repertoire sequencing market is segmented into assay kits, software and services. The assay kits is expected to be the leading segment in the immune repertoire sequencing market and grow at a CAGR of 7.7% over the forecast period.

 

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/14911

 

Based on application, the immune repertoire sequencing market is segmented into cancer immunotherapy, infectious diseases, vaccine development and efficacy, transplant rejection & tolerance, autoimmune disease and biomarker discovery.

 

The cancer immunotherapy segment in the immune repertoire sequencing market is expected to account a high revenue share and grow at a CAGR of 8.7% over the forecast period. Based on end users, the immune repertoire sequencing market is segmented into academic institutes and research centres. The research centres is expected to be the leading segment in the immune repertoire sequencing market over the forecast period, growing at a CAGR of 7.6%.

 

The growth of the immune repertoire sequencing market is primarily driven by increasing prevalence of cancer and other infectious diseases and growing awareness for development of cell-mediated immunotherapies globally.

 

In addition, other factors which is expected to propel the growth of the global Immune Repertoire Sequencing market include increase in healthcare expenditure, demand for genomic based research, increase in sequencing based projects, advancement in sequencing tools (pre-sequencing, bioinformatics solutions and cloud computing). Besides, exceptional developments by China and Japan for integration of new technologies in biomedical research including advancement in genome sequencing is also expected to propel the growth of the immune repertoire sequencing market.

 

The substantial price drop in high throughput sequencing is also expected to contribute to the growth of the immune repertoire sequencing market, particularly in underdeveloped countries of Latin America and MEA.

 

This report assesses the trends that are driving the growth of each segment of the immune repertoire sequencing market on the global as well as regional level, and offers potential takeaways that could prove substantially useful for the manufacturers planning to enter the immune repertoire sequencing market.

 

North America accounted a high revenue share in 2017, and is expected to be the dominant regional market for immune repertoire sequencing over the forecast period. The U.S. immune repertoire sequencing market is expected to hold a large share in North America and is expected to grow at a CAGR of 6.7% over the forecast period.

Large presence of globally renowned companies in high-throughput sequencing and increased scale of sequencing projects in the region is expected to increase the adoption of immune repertoire sequencing. Besides, the leading academic universities and research centers are based in North America, which is also expected to the surge the adoption of immune repertoire sequencing methods.

 

The Europe and Asia Pacific immune repertoire sequencing markets collectively will grow at CAGRs of 7.3% and 9.9 %, respectively, over the forecast period. The Latin America and Middle East and Africa immune repertoire sequencing markets are estimated to expand at CAGRs of 5.8% and 4.8%, respectively, over the forecast period.

 

Consistent investment in development of the healthcare sector in terms of research and services through governmental and private capital funding will drive the demand for immune repertoire sequencing in the region by implication of sequencing tools. High prevalence of infectious and other diseases is one of the key factors expected to drive the growth of the immune repertoire sequencing market in Middle East and Africa.

 

For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/14911

 

Company Profile

  • Illumina, Inc.
  • Pacific Biosciences of California, Inc
  • Agilent Technologies, Inc
  • Oxford Nanopore Technologies, Ltd
  • QIAGEN N.V.
  • Thermo Fisher Scientific
  • F. Hoffmann-La Roche Ltd
  • BGI
  • Takara Bio, Inc
  • Others.

In this report, we have discussed the individual strategies followed by these companies regarding the improvements in their products, new market strategies, market consolidation and advanced R&D initiatives. The report has been concluded with the key takeaways of the players present in the immune repertoire sequencing market and the new players planning to enter the market.